The Efficacy and Safety of Infliximab Therapy for Refractory Kawasaki Disease in Infants

Pediatr Infect Dis J. 2020 Aug;39(8):e219. doi: 10.1097/INF.0000000000002677.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Child
  • Humans
  • Immunoglobulins, Intravenous
  • Infant
  • Infliximab
  • Japan
  • Mucocutaneous Lymph Node Syndrome*

Substances

  • Antibodies, Monoclonal
  • Immunoglobulins, Intravenous
  • Infliximab